Nordea Investment Management AB Has $3.15 Million Holdings in United Therapeutics Corporation $UTHR

Nordea Investment Management AB raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 50.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,914 shares of the biotechnology company’s stock after purchasing an additional 3,664 shares during the quarter. Nordea Investment Management AB’s holdings in United Therapeutics were worth $3,146,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Cambridge Investment Research Advisors Inc. raised its stake in shares of United Therapeutics by 31.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 9,179 shares of the biotechnology company’s stock valued at $2,830,000 after purchasing an additional 2,211 shares during the period. Robeco Institutional Asset Management B.V. raised its stake in shares of United Therapeutics by 17.9% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 226,287 shares of the biotechnology company’s stock valued at $69,757,000 after purchasing an additional 34,362 shares during the period. Diversified Trust Co raised its stake in shares of United Therapeutics by 139.8% in the 1st quarter. Diversified Trust Co now owns 1,842 shares of the biotechnology company’s stock valued at $568,000 after purchasing an additional 1,074 shares during the period. Achmea Investment Management B.V. raised its stake in shares of United Therapeutics by 61.1% in the 1st quarter. Achmea Investment Management B.V. now owns 59,180 shares of the biotechnology company’s stock valued at $18,243,000 after purchasing an additional 22,434 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after purchasing an additional 376 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at approximately $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Insiders have sold 329,935 shares of company stock valued at $135,017,892 in the last quarter. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

United Therapeutics stock opened at $422.53 on Wednesday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48. The stock has a market capitalization of $19.06 billion, a P/E ratio of 16.49, a PEG ratio of 4.72 and a beta of 0.66. The stock has a 50-day simple moving average of $390.76 and a 200 day simple moving average of $329.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the previous year, the business posted $5.85 EPS. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. Research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent research reports. Royal Bank Of Canada initiated coverage on United Therapeutics in a research note on Friday, September 26th. They issued an “outperform” rating and a $569.00 price target on the stock. Bank of America raised their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Morgan Stanley raised their price objective on United Therapeutics from $328.00 to $435.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. HC Wainwright raised their price objective on United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a report on Friday, September 5th. Finally, Wells Fargo & Company began coverage on United Therapeutics in a report on Monday. They issued an “underweight” rating and a $414.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $461.62.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.